Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer.

Cancer immunology, immunotherapy : CII - 24 Mar 2026

Yoshichika Ryo, Mukohara Fumiaki, Yamada Kotaro, Nagasaki Joji, Watanabe Hiroko, Ueda Youki, Suzawa Ken, Shien Kazuhiko, Toyooka Shinichi, Ishino Takamasa, Togashi Yosuke

Abstract excerpt

BACKGROUND: Epidermal growth factor receptor (EGFR) mutations represent one of the most frequent oncogenic driver in non-small cell lung cancer (NSCLC). Amivantamab, a bispecific antibody targeting EGFR and MET proto-oncogene, receptor tyrosine kinase (MET), has demonstrated clinical benefit in EGFR-mutant NSCLC through dual blockade, but its immunological role in human clinical specimens, especially...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Bispecific
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to CD8-Positive T-Lymphocytes

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Lymphocytes, Tumor-Infiltrating

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins c-met

Source

Open in PubMed Open full text

Identifiers

PMID: 41874698
DOI: 10.1007/s00262-026-04369-0
PMCID: PMC13013883

Genes

EGFR
MET
CD28

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 22 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer.PMID 41874698Read ↗

Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancerSemantic proximity Read ↗

Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications.Semantic proximity Read ↗

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC.Semantic proximity Read ↗

Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage TrogocytosisSemantic proximity Read ↗

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.Semantic proximity Read ↗

Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.Semantic proximity Read ↗

Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.Semantic proximity Read ↗

<p>Immunotherapy after EGFR‑TKI treatment in advanced non‑small cell lung cancer: Current status and future perspectives (Review)</p>.Semantic proximity Read ↗

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.Semantic proximity Read ↗

Amivantamab: A New Hope in Targeting Non-small Cell Lung Cancer.Semantic proximity Read ↗

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis.Semantic proximity Read ↗

MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.